Recombinant bovine growth hormone-induced reduction of atrial natriuretic peptide is associated with improved left ventricular contractility and reverse remodeling in cardiomyopathic UM-X7.1 hamsters with congestive heart failure

Growth Hormone and IGF Research

Volumn 17, Issue 2, 2007, Pages 96-103

  Mulumba, Mukandila ^a   Céméus, Catia ^a   Dumont, Louis ^a   du Souich, Patrick ^a   Ong, Huy ^a   Marleau, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Cardiomyopathic hamsters; Growth hormone; Myosin heavy chain; Remodeling

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MESSENGER RNA; MYOSIN HEAVY CHAIN; RECOMBINANT GROWTH HORMONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HAMSTER; HEART DILATATION; HEART HYPERTROPHY; HEART LEFT VENTRICLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEART VOLUME; ISOLATED HEART; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; SHORT COURSE THERAPY;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CATTLE; CRICETINAE; GROWTH HORMONE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; INSULIN-LIKE GROWTH FACTOR I; MESOCRICETUS; MYOCARDIAL CONTRACTION; MYOSIN HEAVY CHAINS; NATRIURETIC PEPTIDES; PROTEIN ISOFORMS; VENTRICULAR FUNCTION, LEFT;

EID: 34147122682     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.12.001     Document Type: Article

References (41)

1. Cuocolo A., Nicolai E., Colao A., Longobardi S., Cardei S., Fazio S., Merola B., Lombardi G., Saccà L., and Salvatore M. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. Eur. J. Nucl. Med. 23 (1996) 390-394
2. Tritos N.A., and Mantzoros C.S. Recombinant human growth hormone: old and novel uses. Am. J. Med. 105 (1998) 44-57
3. Fazio S., Sabatini D., Capaldo B., Vigorito C., Giordano A., Guida R., Pardo F., Biondi B., and Saccà L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334 13 (1996) 809-814
4. Adamopoulos S., Parissis J.T., Georgiadis M., Karatzas D., Paraskevaidis J., Kroupis C., Karavolias G., Koniavitou K., and Kremastinos D.Th. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am. Heart J. 144 2 (2002) 359-364
5. Jose V.J., Zechariah T.U., George P., and Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J. 51 2 (1999) 183-185
6. Perrot A., Ranke M.B., Dietz R., and Osterziel K.J. Growth hormone treatment in dilated cardiomyopathy. J. Card. Surg. 16 2 (2001) 127-131
7. Napoli R. Growth hormone, vascular reactivity, and heart failure. Eur. J. Clin. Pharmacol. 62 Suppl.13 (2006) 141-144
8. Parissis J.T., Adamapoulos S., Karatzas D., Paraskevaidis J., Livanis E., and Kremastinos D. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur. J. Cardiovasc. Prev. Rehabil. 12 (2005) 164-168
9. Omerovic E., Bollano E., Mobini R., Kujacic V., Madhu B., Soussi B., Fu M., Hjalmarson A., Waagstein F., and Isgaard J. Growth hormone improves bioenergetics and decreases catecholamines in postinfarct rat hearts. Endocrinology 141 12 (2000) 4592-4599
10. Grimm D., Cameron D., Griese D.P., Riegger G.A., and Kromer E.P. Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc. Res. 40 (1998) 297-306
11. Cittadini A., Grossman J.D., Napoli R., Katz S.E., Strömer H., Smith R.J., Clark R., Morgan J.P., and Douglas P.S. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J. Am. Coll. Cardiol. 29 5 (1997) 1109-1116
12. Cittadini A., Isgaard J., Monti M.G., Casaburi C., Di Gianni A., Serpico R., Iaccarino G., and Sacca L. Growth hormone prolongs survival in experimental postinfarction heart failure. J. Am. Coll. Cardiol. 41 12 (2003) 2154-2163
13. Tivesten A., Caidahl K., Kujacic V., Sun X.Y., Hedner T., Bengtsson B.A., and Isgaard J. Similar cardiovascular effects of growth hormone and insulin-like growth factor-I in rats after experimental myocardial infarction. Growth Horm. IGF Res. 11 3 (2001) 187-195
14. Jin H., Yang R., Lu H., Ogasawara A.K., Li W., Ryan A., Peale F., and Paoni N.F. Effects of early treatment with growth hormone on infarct size survival and cardiac gene expression after acute myocardial infarction. Growth Horm. IGF Res. 12 (2002) 208-215
15. Jin H., Yang R., Gillett N., Clark R.G., Ko A., and Paoni N.F. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J. Cardiovasc. Pharmacol. 26 (1995) 420-425
16. Duerr R.L., McKirnan M.D., Gim R.D., Clark R.G., Chien K.R., and Ross Jr. J. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 93 (1996) 2188-2196
17. Rothblat G.H., de la Llera-Moya M., Favari E., Yancey P.G., and Kellner-Weibel G. Cellular cholesterol flux studies: methodological considerations. Atherosclerosis 163 (2002) 1-8
18. Yang R., Bunting S., Gillett N., Clark R.G., and Jin H. Effects of growth hormone in rats with postinfarction left ventricular dysfunction. Cardiovasc. Drug Ther. 9 (1995) 125-131
19. Ryoke T., Gu Y., Mao L., Hongo M., Clark R.G., Peterson K.L., and Ross Jr. J. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation 100 16 (1999) 1734-1743
20. Marleau S., Lapointe N., Massicote J., Céméus C., Jasmin G., Dumont L., Sirois M.G., Rouleau J.L., du Souich P., and Ong H. Effect of chronic treatment with bovine recombinant growth hormone on cardiac dysfunction and lesion progression in UM-X7.1 cardiomyopathic hamsters. Endocrinology 143 12 (2002) 4846-4855
21. Larose P., Meloche S., du Souich P., Deléan A., and Ong H. Radioimmunoassay of atrial natriuretic factor: human plasma levels. Biochem. Biophys. Res. Commun. 130 (1985) 553-558
22. Gosselin H., Qi X., and Rouleau J.L. Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarction. Can. J. Physiol. Pharmacol. 76 (1998) 53-62
23. Mohan S.B., Parker M., Wehbi M., and Douglass P. Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure. Cleveland Clin. J. Med. 69 6 (2002) 481-487
24. Isgaard J., Bergh C.-H., Caidahl K., Lomsky M., Hjalmarson A., and Bengtsson B.-A. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19 11 (1998) 1704-1711
25. Osterziel K.J., Strohm O., Schuler J., Friedrich M., Hänlein D., Willenbrock R., Anker S.D., Poole-Wilson P.A., Ranke M.B., and Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351 9111 (1998) 1233-1237
26. Jasmin G., and Eu H.Y. Cardiomyopathy of hamster dystrophy. Ann. NY Acad. Sci. 317 1 (1979) 46-58
27. Jasmin G., and Proschek L. Hereditary polymyopathy and cardiomyopathy in the syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM-X7.1 line. Muscle & Nerve 5 (1982) 20-25
28. Lu C., Schwartzbauer G., Sperling M.A., Devaskar S.U., Thamotharan S., Robbins P.D., McTiernan C.F., Liu J.-L., Jiang J., Franck S.J., and Menon R.K. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J. Biol. Chem. 276 25 (2001) 22892-22900
29. Le Roith D., Bondy C., Yakar S., Liu J.-L., and Butler A. The somatomedin hypothesis: 2001. Endocrine Rev. 22 1 (2001) 53-74
30. Gertz E.W. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog. Exp. Tumor Res. 16 (1972) 242-260
31. Cabrera J.R. Idiopathic dilated cardiomyopathy. Elastic parallel element dysfunction as a physiological hypothesis for ventricular failure. Med. Hypotheses 53 (1999) 260-262
32. Thibault G., Nemer M., Drouin J., Lavigne J.P., Ding J., Charbonneau C., Garcia R., Genest J., Jasmin G., Sole M., and Cantin M. Ventricles as a major site of atrial natriuretic factor synthesis and release in cardiomyopathic hamsters with heart failure. Circ. Res. 65 (1989) 71-82
33. Cárnio E.C., Jankowski M., Mukaddam-Daher S., Gorska I., Antunes-Rodrigues J., and Gutkowska J. Elevated levels of natriuretic peptides in lungs of hamsters with genetic cardiomyopathy. Regul. Peptides 70 1 (1997) 67-73
34. Kuwahara K., Saito Y., Takano M., Arai Y., Yasuno S., Nakagawa Y., Takahashi N., Adachi Y., Takemura G., Horie M., Miyamoto Y., Morisaki T., Kuratomi S., Noma A., Fujiwara H., Yoshimasa Y., Kinoshita H., Kawakami R., Kishimoto I., Nakanishi M., Usami S., Saito Y., Harada M., and Nakao K. NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. EMBO J. 22 (2003) 6310-6321
35. Langenickel T., Pagel I., Höhnel K., Dietz R., and Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 278 (2000) H1500-H1506
36. 2+ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc. Res. 40 1 (1998) 64-73
37. Hongo M., Ryoke T., Schoenfeld J., Hunter J., Dalton N., Clark R., Lowe D., Chien K., and Ross Jr. J. Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res. Cardiol. 95 (2000) 431-441
38. Chien K.R., Knowlton K.U., Zhu H., and Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5 (1991) 3037-3046
39. Gidh-Jain M., Huang B., Jain P., Gick G., and El-Sherif N. Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J. Mol. Cell Cardiol. 30 (1998) 627-637
40. Cameron V.A., and Ellmers L.J. Minireview: Natriuretic peptides during development of the fetal heart and circulation. Endocrinology 144 (2003) 2191-2194
41. Minieri M., Fiaccavento R., Carosella L., Peruzzi G., and Di Nardo P. The cardiomyopathic hamster as model of early myocardial aging. Mol. Cell. Biochem. 198 (1999) 1-6